Skip to main content

Table 1 Clinical characteristics of patients with chronic hepatitis C virus infection

From: Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients

Baseline characteristics Non-SVR (n = 246) SVR (n = 377) P-value
Female 85 (34.6%) 128 (34.0%) 0.88
Age (years), 51.9 ± 8.4 50.0 ± 10.1 0.01
Body mass index (kg/m2) 24.6 ± 3.4 24.5 ± 3.5 0.71
Alcohol drinking 138 (68.7%) 155 (62.5%) 0.17
Diabetes mellitus 51 (25.5%) 55 (22.5%) 0.47
Genotype
1 131 (53.3%) 147 (39.0%) <0.005
2 0 1 (0.3%)  
3 101 (41.1%) 186 (49.3%)  
6 14 (5.7%) 43 (11.4%)  
Pre-treatment HCV-RNA (IU/ml) 6.02 ± 0.60 5.81 ± 0.88 0.003
Pre-treatment ALT level (U/L) 106.2 ± 158.3 102.5 ± 75.8 0.98
Pre-treatment AST level (U/L) 87.3 ± 130.2 73.4 ± 52.1 0.046
Advanced fibrosis (stage 2–4) 76 (51.0%) 73 (36.0%) 0.005
PEG-IFN alfa-2a 109 (55.6%) 145 (58.2%) 0.58
  1. Data represent as n (%), mean ± SD. AST aspartate aminotransferase, ALT alanine aminotransferase, HCV RNA hepatitis C virus RNA, PEG-IFN pegylated interferon, SVR sustained virologic response, SD standard deviation